Navigation Links
Drugs used for cancer-associated anemia linked with increased risk of blood clots, death

Treating anemia with a class of drugs known as erythropoiesis-stimulating agents (ESAs) is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs) and death among patients with cancer, according to an article in the February 27 issue of JAMA.

The ESAs erythropoietin and darbepoetin are widely used to treat anemia in patients with cancer. Some studies have indicated that there may be a higher risk of venous thromboembolism (VTE) with these medications, but it has not been known if there is an associated increased risk of death, according to background information in the article.

Charles L. Bennett, M.D., Ph.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues examined the rate of VTE and death associated with ESA administration for treatment of anemia among patients with cancer by conducting a review of phase 3 trials.

The researchers identified 51 clinical trials with 13,611 patients to examine survival. Analysis of the data indicated that the risk of death was significantly higher for patients with cancer who were treated with ESA vs. the control (placebo) group.

Venous thromboembolism was evaluated for 38 trials that included 8,172 patients. The researchers found that there was a significantly increased risk (57 percent) of VTE among patients treated with ESA (334 events among 4,610 patients treated with ESA vs. 173 events among 3,562 control patients).

These risks are important given the prevalence of ESA use as a supportive care drug among patients with cancer as well as the dissemination of a series of safety advisories by the Food and Drug Administration (FDA) and ESA manufacturers, the authors write.

Safety concerns account in large part for changes observed in patterns of use, reimbursement policies, clinical guidelines, and FDA-approved package inserts pertaining to ESAs in the oncology setting. Our findings, in conjunction with basic science reports on erythropoietin and erythropoietin receptors in solid cancers, raise concern about ESA safety for patients with cancer.


Contact: Marla Paul
JAMA and Archives Journals

Related medicine news :

1. Anemia Drugs for Cancer Patients Increase Death Risk
2. China Nepstar Chain Drugstore to Acquire 68 Drugstores from Ningbo New Century Medical Ltd.
3. Many Patients Fail to Take Drugs After Heart Attack
4. Cure Diabetes with Weight Loss, Not Drugs, Expert Says
5. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
6. The Northern Illinois University Murders Due to Chemical Imbalances or Chemical Balancers - Drugs? - Fred A. Baughman Jr., MD, Neurologist/Child Neurologist
7. New understanding of how big molecules bind will lead to better drugs, synthetic organic materials
8. Cholesterol-Lowering Drugs May Ease Irregular Heartbeat
9. Free Drugs After Heart Attack Would Save Money, Lengthen Lives
10., inc. to Present at the Upcoming Jefferies 4th Annual Internet Conference and the Morgan Stanley Technology Conference
11. DNA with a twist: New company to search for cancer drugs and antibiotics
Post Your Comments:
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: